Oct. 25, 2000--Nymox Pharmaceutical Corporation (Nasdaq:NYMX) -- A new article published in the Fall 2000 issue of the Anti-Aging Medical News has recommended Nymox's urine test as an aid to the physician in testing for Alzheimer's disease (AD).
The Anti-Aging Medical News is the official publication of the American Academy of Anti-Aging. In reference to Nymox's urinary neural thread protein (NTP) test the article states "a recent breakthrough in the laboratory investigation of dementia and Alzheimer's disease may become a new standard for testing mental deterioration in the aging population".
Nymox recently announced the launch of the new AlzheimAlert(TM) test, its most recent innovation in NTP testing. The Company also announced that 35 new sales representatives will be involved in the launch.
The article refers to recent peer-reviewed medical literature on Nymox's test. According to the new article, "NTP is a valuable aid to a physician because it is an early and accurate marker for AD".
Commenting on the clinical importance of the NTP urine test, the new article further states that Nymox's test is "a potential means of tracking the effectiveness of treatment and of better managing the patient's care".
Dr. Michael Munzar, Medical Director of Nymox, said "this is another strong sign that NTP is rapidly gaining national recognition as a highly useful tool to help the physician in the diagnosis and treatment of cognitive problems in our elderly population".
Nymox's NTP test measures neural thread protein (NTP) in urine. NTP is the only proven non-invasive test of its kind, which has been shown in independent studies and numerous peer-reviewed publications in the medical literature to be highly useful as an aid to the diagnosis of dementia and Alzheimer's disease. The Nymox NTP marker has been referred to as a "successful in vitro diagnostic" by the official publication of the American Association for Clinical Chemistry (1999, 25, 9). Independent verification of the usefulness of NTP in Alzheimer's was published by researchers from Stanford University in the official journal of the American Academy of Neurology (Neurology 2000, 1498-1504). A recent peer-reviewed report on the usefulness of Nymox's test appeared in the current issue of Alzheimer's Reports published in England (July 2000).
Nymox's breakthrough test technology has been widely recognized in medical journals and textbooks and other publications such as Clinica, Genetic Engineering News, Clinical Laboratory News, Lab Medica, Clinical Laboratory International, Modern Maturity, Saturday Evening Post, Forbes, Fortune, Business Week, Time, New York Times, Washington Post, and many others.
Nymox Pharmaceutical Corporation pioneers in the research and development of products for the diagnosis and treatment of Alzheimer's disease, an affliction of more than 15 million people around the world. Nymox offers the world's only accurate, non-invasive urinary test to aid in the diagnosis of the disease, and is developing proprietary spheron-based drug therapies that could lead to effective treatment of Alzheimer's disease. Nymox recently acquired a majority interest in Serex, Inc., a New Jersey corporation with proprietary tests under development in the fields of geriatric, cardiovascular, metabolic and musculoskeletal disease. Nymox is also developing a new class of antibacterial agents for the treatment of urinary tract and other bacterial infections in humans which have proved highly resistant to conventional antibiotic treatments and for the treatment of E. coli 0157:H7 bacterial contamination in hamburger meat and other food and drink products. Nymox Pharmaceutical Corporation is headquartered in Montreal, with a facility in Maywood, NJ. Its stock is traded on NASDAQ with the symbol NYMX. More information is available at nymox.com.
Jim |
